IREB2 and cancer: In summary, IRP2 inhibitors induce iron deficiency in cancer cells, resulting in mitochondrial dysfunction and cell mortality by impairing DNA repair and disrupting cell cycle checkpoints, thereby enhancing radiation sensitivity.